Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pain drug may reduce breathing risks during routine scopes

NCT ID NCT07187765

Symptom relief Sponsor: Shiyou Wei Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study compared two painkillers—oliceridine and sufentanil—given alongside propofol sedation during gastrointestinal endoscopy. The goal was to see if oliceridine causes fewer episodes of low blood oxygen (hypoxemia) than the standard drug. Over 500 adults participated, and researchers tracked oxygen levels throughout the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oliceridine (TRV130)
What this could lead to
If it works, oliceridine could become a safer painkiller option for routine endoscopic procedures, reducing the risk of low oxygen levels during sedation.
What could go wrong
This is a single-center, completed trial with 508 participants. The results may not apply to all patients or settings, and oliceridine may not prove safer than the standard drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

508 people

The number who actually took part.

Started

Sep 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged ≥ 18 years. * Scheduled to undergo elective gastrointestinal endoscopy (gastroscopy or colonoscopy). * American Society of Anesthesiologists (ASA) physical status I-III. * No history of severe cardiopulmonary dysfunction or other major systemic disease. Exclusion Criteria: * Dementia or any cognitive impairment precluding provision of informed consent. * Known contraindication to oliceridine. * Chronic (long-term) opioid use. * Any other medical or logistic condition that, in the investigator's judgment, makes the participant unsuitable for the study (specify reason).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal endoscopy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal endoscopy Hypoxemia during surgery

Contacts and locations

Locations

  • Tianmen First People's Hospital

    Tianmen, Hubei, 431700, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.